Dr. Sergio D. Iñiguez
Dr. Iñiguez' research program evaluates the developmental neurobiology of stress-induced illnesses, such as anxiety and depression, using simple non-human murine models. To do this, his preclinical laboratory adopts a multidisciplinary approach (behavioral, molecular, and pharmacological) to examine how exposure to social stress and/or psychotropic agents (i.e., fluoxetine, ketamine) influence responses to drugs of abuse, as well as memory-related performance, in a developmental and sex-specific manner.
1. Warren BL, Mazei-Robison MS, Robison AJ, Iñiguez SD. (2020). Can I get a Witness? Using vicarious social defeat stress to study mood-related illnesses in traditionally understudied populations. Biological Psychiatry. PMID: 32228871.
2. Garcia-Carachure I, Flores-Ramirez FJ, Castillo SA, Themann A, Arenivar MA, Preciado-Piña J, Zavala AR, Lobo MK, Iñiguez SD. (2020). Enduring effects of adolescent ketamine exposure on cocaine- and sucrose-induced reward in male and female C57BL/6 mice. Neuropsychopharmacology. PMID: 32165718.
3. Flores-Ramirez FJ, Themann A, Sierra-Fonseca JA, Garcia-Carachure I, Castillo SA, Rodriguez M, Lira O, Preciado-Piña J, Warren BL, Robison AJ, Iñiguez SD. (2021). Adolescent fluoxetine treatment mediates a persistent anxiety-like outcome in female C57BL/6 mice that is ameliorated by fluoxetine re-exposure in adulthood. Scientific Reports. PMID:33833356.
4. Iñiguez SD, Flores-Ramirez FJ, Themann A, Lira O. (2021). Adolescent fluoxetine exposure induces persistent gene expression changes in the hippocampus of adult male C57BL/6 mice. Molecular Neurobiology. PMID:33241493.
Ph.D., Florida State University (2011)
Professor and Associate Chair
PSYC 4345 Behavioral Neuroscience